Pfizer Inc. (NYSE:PFE) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 6:00 PM ET Company Participants Albert Bourla - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good afternoon, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be hosting a fireside chat today with Albert Bourla, Chairman and CEO of Pfizer. So, Albert, happy New Year. Thanks for joining us. I know you want to make some quick opening remarks and th ...

Pfizer Inc. (NYSE:PFE) J.P. Morgan 42nd Annual Healthcare Conference January 9, 2024 6:00 PM ET Company Participants Albert Bourla - Chairman and Chief Executive Officer Conference Call Participants Chris Schott - J.P. Morgan Chris Schott Good afternoon, everybody. I'm Chris Schott at J.P. Morgan, and it's my pleasure to be hosting a fireside chat today with Albert Bourla, Chairman and CEO of Pfizer. So, Albert, happy New Year. Thanks for joining us. I know you want to make some quick opening remarks and th ...

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has approved TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) in whom chemotherapy is not clinically indicated. With this approval, TALZENNA is now the first and only PARP inhibitor licensed in the European Union for use with XTANDI for pati ...

Pfizer (PFE) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this drugmaker have returned +2.4% over the past month versus the Zacks S&P 500 composite's +2.9% change. The Zacks Large Cap Pharmaceuticals industry, to which Pfizer belongs, has gained 6.6% over this period. Now the key question is: Where could the stock be headed in the near term?Although media reports or ...

Pfizer Inc. shares PFE, were downgraded to market perform from outperform at TD Cowen on Thursday, as analysts see upcoming patent expirations and shaky confidence in the drugmaker’s management clouding the outlook. Despite a brutal 2023, when the stock dropped more than 40%, it’s “tough to pound the table even from these levels,” the analysts wrote, adding that expected strong earnings growth through 2026 will be weighed down longer term by losses of market exclusivity on key drugs like the blood thinner ...

Pfizer (PFE) closed at $29.73 in the latest trading session, marking no change from the prior day. This move was narrower than the S&P 500's daily loss of 0.8%. Elsewhere, the Dow saw a downswing of 0.76%, while the tech-heavy Nasdaq depreciated by 1.18%.Prior to today's trading, shares of the drugmaker had gained 2.2% over the past month. This has lagged the Medical sector's gain of 5.8% and the S&P 500's gain of 3.4% in that time.The upcoming earnings release of Pfizer will be of great interest to investo ...

Pfizer Inc (NYSE:PFE) stock moved steadily lower in 2023, closing 11 out of 12 months lower, with March as the only gainer. Though the shares have been on the rise since their Dec. 13 10-year low of $25.76 -- a result of the company's disappointing 2024 forecast -- PFE might not be in the clear just yet. Per data from Schaeffer's Senior Quantitative Analyst Rocky White, Pfizer stock is at the top of the list of the worst stocks to own in January. In the past 10 years, the equity has finished lower eight tim ...

JHVEPhoto Overview I've always preferred to invest with a data-driven long term outlook. Therefore, I look for quality opportunities where I can grow my income and capture a superior total return. With some entities, where you start an initial position really matters most. I think the price level of Pfizer (NYSE:PFE) is one of these opportunities based on the dividend coverage and growth, valuation metrics, and future growth outlook. The current price under $30/share offers an opportunity to lock in potenti ...

Drugmakers including Pfizer, Sanofi and Takeda Pharmaceutical plan to raise prices in the US on more than 500 drugs in early January, according to data analyzed by healthcare research firm 3 Axis Advisors.Excluding different doses and formulations, more than 140 brands of drugs will have their prices raised next month, the data showed.The expected price hikes come as the pharmaceutical industry gears up for the Biden Administration to publish significantly discounted prices for 10 high-cost drugs in Septem ...

You might call it a "Pfizzle."In late 2021, Pfizer (PFE 0.70%) stock was at an all-time high. The company had pulled off a near miracle with its rapid development of a COVID-19 vaccine.It followed that success with the launch of an effective oral COVID pill. Both became megablockbusters, with the vaccine (Comirnaty) generating global sales of $37.8 billion and the antiviral therapy (Paxlovid) raking in an additional $18.9 billion in 2022. It's a much different story today. Pfizer has lost more than half of ...